[ZURICH] Novartis has received approval from the US Food and Drug Administration for its Beovu drug to treat a cause of vision loss, the Swiss pharmaceuticals company said on Tuesday.

[ZURICH] Novartis Chief Executive Vas Narasimhan, facing an uproar over data manipulation involving US$2.1 million gene therapy Zolgensma, pledged on Monday to tell regulators quickly if credible...

[BEIJING] China has expanded a pilot drug bulk-buying programme to almost the entire country in an attempt to negotiate lower prices from drug manufacturers, heaping fresh pressure on...

CHEMICALS and biotech company Lonza Group will purchase a sterile drug product fill-and-finish facility in Stein, Switzerland, from Novartis.

[NEW YORK] Sanofi named Novartis AG's Paul Hudson as the French drugmaker's next chief executive officer, replacing Olivier Brandicourt with one of the top managers at its Swiss rival.

[ZURICH] Swiss drugmaker Novartis on Friday won US approval for its gene therapy Zolgensma for spinal muscular atrophy (SMA), the leading genetic cause of death in infants, and priced the one-time...

[BENGALURU] Swiss drugmaker Novartis AG said on Wednesday it agreed to acquire Japan-headquartered Takeda Pharmaceutical Company's dry eye drug Xiidra for an upfront payment of US$3.4 billion to...

[MINNEAPOLIS] Novartis AG's Zolgensma, a gene therapy under review for treating children with a rare inherited disease that typically kills before the age of 2, also appears promising for a...

[ZURICH] Novartis's generics chief is quitting after the Swiss drugmaker sold parts of the business and initiated an 18-month revamp, fueling speculation about an eventual spin-off or sale.

[ZURICH] Novartis on Monday exercised its option to license an RNA-targeting cardiovascular drug from Ionis Pharmaceuticals as the Swiss company aims to surround its heart-failure blockbuster...